(Reuters) – Sanofi’s rare disease unit Genzyme is pulling leukaemia drug Campath to prepare for its launch under a different dosage and as a multiple sclerosis treatment that will be branded as Lemtrada.The withdrawal, meant to prevent the off-label use of Campath as a multiple sclerosis drug, is al

ประเทศไทยมีระบบหลักประกันสุขภาพถ้วนหน้าช่วยให้คนไทยทุกคนได้เข้าถึงการรักษาพยาบาลได้ฟรี ทว่าค่าใช้จ่ายที่ตามมาแท้จริงแล้วคือสิ่งที่ประเทศต้องแบกรับ ภาระค่าใช้จ่ายด้านสุขภาพของประเทศเพิ่มขึ้นตามความต้องการการรักษาพยาบาลของคนไทย จากคำกล่าวของผู้คร่ำหวอดในวงการ นพ.สุวิทย์ วิบุลผลประเสริฐ SAFE report คือ

Yot Teerawattananon programme leader1, Alia Luz project associate2, Churnrurtai Kanchanachitra director, Mahidol University Global Health 3, Sripen Tantivess senior researcher 1, On behalf of the Prince Mahidol Award Conference secretariat 1Health Intervention and Technology Assessment Program (

Abstract There seems to be a general agreement amongst practitioners of economic evaluations, including Health Technology Assessment, that the explicit statement of a perspective is a necessary element in designing and reporting research. Moreover, there seems also to be a general presumption that

Cases of drug-resistant tuberculosis (TB) in the UK have risen by over a quarter in the last year, the Health Protection Agency (HPA) has revealed.In 2011, 431 cases did not respond to antibiotic treatment compared to 342 in 2010, the HPA said. About 550 more cases of TB were disgnosed in 2011.The a

Abstract Thailand is encountering challenges to introduce the high-cost sofosbuvir for chronic hepatitis C treatment as part of the Universal Health Care’s benefit package. This study was conducted in respond to policy demand from the Thai government to assess the value for money and budget impac

Reviewing the evidence on effectiveness and cost-effectiveness of HIV prevention strategies in Thailand. Pattanaphesaj J, Teerawattananon Y.  Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand Backgroud: Following universal access to antiretroviral

This was the presentation made to consult with experts from the UK during a visit by Dr. Paramjit Gill, Reader in Primary Care Research and Dr. Rachel Foskett-Tharby, Research Fellow National Collaborating Centre for Indicator Development (NCCID), Primary Care Clinical Sciences, University of Bi